205 related articles for article (PubMed ID: 34049987)
1. Tumor Sink Effect in
Gafita A; Wang H; Robertson A; Armstrong WR; Zaum R; Weber M; Yagubbayli F; Kratochwil C; Grogan TR; Nguyen K; Navarro F; Esfandiari R; Rauscher I; Menze B; Elashoff D; Delpassand ES; Herrmann K; Czernin J; Hofman MS; Calais J; Fendler WP; Eiber M
J Nucl Med; 2022 Feb; 63(2):226-232. PubMed ID: 34049987
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Monosodium Glutamate on
Armstrong WR; Gafita A; Zhu S; Thin P; Nguyen K; Alano R; Lira S; Booker K; Gardner L; Grogan T; Elashoff D; Allen-Auerbach M; Dahlbom M; Czernin J; Calais J
J Nucl Med; 2021 Sep; 62(9):1244-1251. PubMed ID: 33509974
[TBL] [Abstract][Full Text] [Related]
4. Antihormonal-Treatment Status Affects
Kluge K; Haberl D; Einspieler H; Rasul S; Gutschmayer S; Kenner L; Kramer G; Grubmüller B; Shariat S; Haug A; Hacker M
J Nucl Med; 2023 Nov; 64(11):1730-1736. PubMed ID: 37734840
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using
Gafita A; Bieth M; Krönke M; Tetteh G; Navarro F; Wang H; Günther E; Menze B; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(9):1277-1283. PubMed ID: 30850484
[TBL] [Abstract][Full Text] [Related]
7. A prospective head-to-head comparison of [
Wang G; Li L; Zhu M; Zang J; Wang J; Wang R; Yan W; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3126-3136. PubMed ID: 37233785
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
9. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on
Siebinga H; Heuvel JO; Rijkhorst EJ; Hendrikx JJMA; de Wit-van der Veen BJ
J Nucl Med; 2023 Jan; 64(1):63-68. PubMed ID: 35680416
[No Abstract] [Full Text] [Related]
11. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
12. Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [
Chen R; Ng YL; Yang X; Zhu Y; Li L; Zhao H; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):896-906. PubMed ID: 37889299
[TBL] [Abstract][Full Text] [Related]
13. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
14. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
15. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
17. Determination of optimal
Wen J; Zhu Y; Li L; Liu J; Chen Y; Chen R
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2086-2095. PubMed ID: 34962583
[TBL] [Abstract][Full Text] [Related]
18. Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen PET-computed tomography and multiparametric MRI.
Sasidharan A; Murthy V; Natarajan A; Agarwal A; Ranagrajan V; Gudi S; Singh S; Popat P
Nucl Med Commun; 2020 Dec; 41(12):1291-1298. PubMed ID: 32941400
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of thresholding methods for the quantification of [
Kim M; Seifert R; Fragemann J; Kersting D; Murray J; Jonske F; Pomykala KL; Egger J; Fendler WP; Herrmann K; Kleesiek J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2196-2209. PubMed ID: 36859618
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Test-Retest Measurement of
Pollard JH; Raman C; Zakharia Y; Tracy CR; Nepple KG; Ginader T; Breheny P; Sunderland JJ
J Nucl Med; 2020 Aug; 61(8):1145-1152. PubMed ID: 31806776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
